

Resource Summary Report

Generated by [RRID](#) on Sep 6, 2026

CD144 (VE-Cadherin) Antibody, APC, REAfinity™

RRID:AB_2655155

Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-100-708, RRID:AB_2655155

Antibody Information

URL: http://antibodyregistry.org/AB_2655155

Proper Citation: Miltenyi Biotec Cat# 130-100-708, RRID:AB_2655155

Target Antigen: CD144 (VE-Cadherin)

Host Organism: human

Clonality: recombinant

Comments: Discontinued: 7-2020; Applications: MACS Flow Cytometry

Antibody Name: CD144 (VE-Cadherin) Antibody, APC, REAfinity™

Description: This recombinant targets CD144 (VE-Cadherin)

Target Organism: human

Clone ID: [REA199]

Antibody ID: AB_2655155

Vendor: Miltenyi Biotec

Catalog Number: 130-100-708

Record Creation Time: 20231110T034436+0000

Record Last Update: 20260901T003816+0000

Ratings and Alerts

No rating or validation information has been found for CD144 (VE-Cadherin) Antibody, APC, REAfinity™.

Warning: Discontinued: 2021

Discontinued: 7-2020; Applications: MACS Flow Cytometry

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 2 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Jung HS, et al. (2021) SOX17 integrates HOXA and arterial programs in hemogenic endothelium to drive definitive lympho-myeloid hematopoiesis. Cell reports, 34(7), 108758.

Hu B, et al. (2016) Epigenetic Activation of WNT5A Drives Glioblastoma Stem Cell Differentiation and Invasive Growth. Cell, 167(5), 1281.